New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
16:19 EDTFLXNFlexion signs worldwide exclusive license with Southwest Research Institute
Flexion Therapeutics announced that it has executed an exclusive worldwide licensing agreement with the Southwest Research Institute, or SwRI, to utilize proprietary microsphere manufacturing technologies for production of Flexion's sustained-release drug candidates, including leading candidate FX006. The SwRI technologies employ a uniquely controlled and continuous atomizing technology that Flexion believes may facilitate efficient scale-up of phase 3 clinical trial material and commercial supply. Flexion has successfully used this technology to produce clinical trial microsphere product for its lead drug candidate FX006, which has been tested in more than 200 patients.
News For FLXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
08:51 EDTFLXNFlexion weakness creates attractive entry point, says RBC Capital
After meeting with Flexion's management, RBC Capital says the company's story is on track, while its catalysts are getting closer as two data points are on track to be reported in Q4. The firm reiterates a $41 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use